DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Market Weekly Report – 15–19 December 2025
Pivot week across Fed, BoE, ECB, US CPI, small-cap rotation and event-driven biotech catalysts.
EN
Overview
Executive Summary
The coming week looks like a genuine pivot week for global markets, with three macro catalysts in sequence that will reshape expectations on rates, growth and inflation. The backdrop is a rotation into small caps and cyclicals, supported by a Fed that has shifted into a less aggressive “pause” mode and by a potential divergence between central banks: the BoE is expected to cut (18 Dec), the ECB is likely to stay on hold, and US CPI (18 Dec) together with labour data will refine the timing of 2026 rate cuts.
Adding a high-volatility setup for biotech – with three event-driven names (MIST just approved, ALDX PDUFA 16 Dec, TLRY riding cannabis policy headlines) – plus a Russell 2000 in a breakout attempt toward new highs, the picture for traders and investors is one of fragmented opportunities, asymmetric risk, and plenty of mean-reversion traps in segments where sentiment has stretched too far.
1) 8–12 December
1) Quick Recap of Last Week (8–12 December)
Index Performance (weekly)
- S&P 500: -0.6%
- Nasdaq 100: -1.6%
- Dow Jones: +1.0%
- Russell 2000: +1.2%
Dominant theme: the week was driven by a strong intrasector rotation: weakness in mega-cap tech/AI (the “Magnificent 7” repriced against higher real rates) and resilience in cyclicals and small caps. The positive Russell versus negative S&P and Nasdaq is coherent with that story. The same pattern shows up in fixed income.
Bonds and the Dollar
The market reacted to two parallel forces:
- Fed communication: a “higher for longer” bias on cuts versus the more aggressive path many had extrapolated for 2026. The median 2026 dot sits around 3.4% (versus the current 3.50–3.75%), which implies only one 25 bps cut in 2026 – much less aggressive than what some narratives suggested earlier in the autumn.
- Inflation and labour data: every surprise – up or down – shifts real yields and therefore drives growth vs. value/cyclical rotations in equities.
Intraday moves in yields and the USD essentially set the timing of risk-on vs. risk-off, adding short-term volatility without yet changing the bigger trend.
Energy and Geopolitics
Attacks on infrastructure (for example the reported Russian-Ukrainian strike on the Yaroslavl refinery, with temporary production suspension) created headline risk on oil and gas, partially offset by concerns around global demand and “growth recession” fears.
The broader Middle East conflict remains in the background, with an intermittent risk premium priced in shipping and defence.
2) Fed
2) Fed Focus: What Happened and What Matters Now
FOMC Decision (10 December)
The Fed cut rates by 25 bps, bringing the target range to 3.50–3.75%. This was in line with market expectations, but the details of the communication and the dot plot were the real surprise.
Key Language from the Fed
- Economy growing at a “moderate” pace
- Inflation “still elevated”
- Uncertainty “high”
- Future decisions data-dependent
This nuance is crucial: the Fed did not promise a quick cutting cycle. It emphasised a cautious, data-driven path instead.
Reserve Operations
The Fed indicated that bank reserves have declined to what it considers “ample” levels and that it can buy short-term Treasuries if needed to keep reserves ample. That means overall financial conditions remain well calibrated, while the Fed keeps a close eye on liquidity.
Internal Dissent
The vote revealed different preferences: some members would have preferred a 50 bps cut (more dovish), others no cut at all (more hawkish). Such open dissent is relatively rare and highlights how divided the Fed is on the future path.
Projections (SEP / Dot Plot) – The Critical Piece
Median projections for 2025 and beyond:
- PCE 2025: ~2.9% (vs. 2% target)
- Core PCE 2025: ~3.0%
- Unemployment 2025: ~4.5%
- Median rate 2025: ~3.6% (already close to the current 3.50–3.75%)
- Median rate 2026: ~3.4% → implies only one 25 bps cut in 2026
- Median rate 2027: ~3.1%
- Long-run rate: ~3.0%
Reuters and other observers have stressed how the Fed looks split and how the dots imply a “higher for longer” pace in 2026 – effectively the opposite of the aggressive-cuts narrative that dominated in September–October.
What to Watch Next Week (Post-FOMC)
- “Second-round” inflation: any surprise in CPI prints (16 and 18 Dec) or in long-term inflation expectations (University of Michigan, 19 Dec) could move real rates and therefore long-duration growth equities.
- Fed speakers: coming out of a “split” meeting, every speech from Powell, Waller, Williams or Bostic (15–17 Dec) will be parsed as an attempt to either “re-align” the committee or signal persistent divergence, affecting the pricing of 2026 cuts.
- Financial conditions: if the market eases too much (strong equity rally + easy credit + tight CDS spreads), Fed communication could lean a bit cooler on cuts to avoid overheating. Right now conditions are moderate, which gives the Fed space to stick to the data-dependent script.
3) Geopolitics
3) Geopolitics: Transmission Channels into Equities
Russia–Ukraine / Energy
Attacks on critical infrastructure (refineries, depots, transport networks) push up the headline risk on crude and refined products. That can affect:
- Inflation expectations (via energy-linked prices and transport services)
- Corporate margins in energy, utilities, transportation
- Sector rotation (positive for Energy, negative for Growth/Tech that are sensitive to real rates)
Historical pattern: markets tend to price an intermittent risk premium – sharp reactions in oil/shipping/defence, then normalisation if there is no clear escalation. The threshold for a “true” long-term escalation remains high, which limits the long-run repricing for now.
Middle East / Routes & Risk Premium
The Red Sea and Strait of Hormuz routes remain under close watch, but current pricing still reflects a limited risk premium unless and until new events force repricing.
US–China / Indo-Pacific and Trade
Trade policy remains central for the “tariffs and inflation” theme. Rising uncertainty about tariffs is often cited as a drag on capex and global consumption. A potential escalation in 2026 could:
- Push up import costs (imported inflation)
- Slow capex in trade-exposed sectors
- Support reshoring and domestically-oriented small caps
4) US Politics
4) Trump Focus: Policy Moves as a Market Factor
The basic chain here is: policy headline → specific sectors → inflation/activity → Fed reaction function.
(A) Tariffs / Trade War (Macro + Sectors)
Reuters has recapped the 2025 “trade war” landscape: baseline tariffs in the 10–20% range on broad imports, with higher levels (25%+) on China under discussion. Possible effects include:
- Prices and supply chains (imported inflation)
- Corporate margins (compression for export-dependent names)
- Trade flows (potential reshoring, re-routing of supply chains)
Market implication: aggressive and unexpected tariffs tend to weigh on growth equities; domestically focused small caps and cyclicals can sometimes benefit from reshoring narratives, depending on how inflation plays out.
(B) Cannabis / Regulation (Policy-Driven Small Caps)
On Friday 12 Dec cannabis names spiked on reports that Trump is considering easing federal restrictions, with a potential rescheduling to Schedule III (from Schedule I). This is classic “headline beta” in small caps: high volatility, gap moves, and an options implied-volatility crush once the decision is known.
Timeline: Trump has floated the idea of an executive order “early December” (possibly around Monday 16 Dec), but there is no firm confirmation. Moves in TLRY and Canopy Growth (CGC) have been violent: +30–50% intraday followed by consolidation.
(C) Immigration / Labour
Decisions around TPS (Temporary Protected Status) and tighter immigration stance feed into the longer-term labour market picture: participation, wage pressure, inflation. The transmission here is slower than tariffs, but still relevant for 2026.
5) Macro Calendar
5) Detailed Economic Calendar (15–19 December)
Monday 15 December
- US: Empire State Manufacturing Index – proxy for manufacturing sentiment; expected to edge lower (post-Fed seasonal pattern).
- US: NAHB Housing Market Index – homebuilder sentiment; relevant for reading housing demand in a still-elevated rates environment.
- US: Fed Speakers (times vary) – could include Powell, Waller, Williams. Each comment will be scrutinised for hints on the 2026 rate path.
Tuesday 16 December
- US: Retail Sales (headline and core) – CRITICAL. December sales drive the consumption narrative; core (ex food/energy) matters for goods-driven inflation.
- US: Flash PMI (Manufacturing and Services) – early read on economic momentum, used to calibrate CPI expectations.
- US: Business Inventories – rising inventories can set up pressure on pricing and margins later on.
- ALDX (Aldeyra): possible communications around the reproxalap PDUFA (decision date 16 Dec) – the FDA may announce in the after-hours window.
Wednesday 17 December
- US: Crude Oil Inventories – impacts energy trend and perceived global demand.
- US: Fed Speakers (Waller, Williams, Bostic indicated in calendars) – final communication round before CPI, important for “resetting” expectations.
Thursday 18 December – Heavy Day (Weekly Turning Point)
This is the most complex day of the week in terms of overlapping catalysts.
UK: Bank of England – Decision (Expected: cut to 3.75%)
- Reuters poll (11 Dec): all 64 economists surveyed expected a 25 bps cut, with market probability around 70–75%.
- Implication: if Bailey delivers the cut as expected, that is dovish for GBP and generally supportive for risk sentiment. A surprise “no cut” would likely mean a sharp GBP rally and a temporary risk-off wobble.
- Context: the BoE was split in November (4 dovish, 5 hawkish), but Bailey has signalled that a reduction in December is likely if the data cooperate.
Eurozone: ECB Decision (Expected: hold)
- Lagarde (10 Dec) stressed that the eurozone is doing better than feared and that the Fed is in a “good position” (no urgent cuts). Futures show near-zero probability of a rate move on 18 Dec.
- Implication: Fed “pause” and ECB “pause” mean the dollar does not receive an extra dovish impulse from Europe; less scope for DXY downside from this angle. A more dovish BoE versus a relatively firmer ECB could weaken GBP versus EUR.
- Lagarde press conference: guidance on 2026 growth will be key; any upward revision would support the “hold” stance.
US: CPI (Consumer Price Index) – Y/Y and M/M, core and headline
- CRITICAL for Fed repricing. A positive surprise (higher CPI) lifts real yields → pressures growth and the small-cap rotation. A downside surprise supports the opposite dynamic.
- Consensus: headline CPI around 2.8% Y/Y, core around 3.3% Y/Y (previous 2.4% and 3.3%).
- Key focus: services inflation and “core goods” staying elevated. The Fed wants “clear disinflation” in core before endorsing aggressive 2026 cuts. This print is the main driver for repricing the dot plot.
US: Initial Jobless Claims
- Labour market proxy; expected around 230–250k. A spike higher is usually read as dovish for the Fed (more slack), while very low claims reinforce the “tight labour market” story.
US: Philly Fed Manufacturing Index
- Early “heat check” for manufacturing; secondary compared to CPI/claims, but still watched.
Friday 19 December
- US: Existing Home Sales – housing momentum; weak data would underline how higher rates are weighing on demand.
- US: University of Michigan Sentiment (revisit) – a downside surprise could highlight “shock” coming from CPI or geopolitical headlines.
Crucial angle: 5–10 year inflation expectations from UofM matter a lot for the Fed; an upside surprise could force a rethink on the path of cuts.
6) Biotech & Small Caps
6) “Hot” Names – Biotech & Small Caps: Catalysts & Volatility Setup
Context: Biotech IV Crush & Event-Driven Moves
The 15–19 December week is dense with PDUFA decisions (MIST on 13 Dec already in the rear-view mirror, ALDX on 16 Dec ahead). The classic biotech setup looks like this:
- Pre-PDUFA: implied volatility tends to rise sharply; calls and puts become expensive in premium terms.
- Post-PDUFA: implied volatility often collapses; options lose a large portion of time value while the underlying gaps up or down.
- Realised volatility: gap moves can be large, but with less implied volatility left to sell afterwards – many volatility strategies shift from pre-event positioning into post-event “IV crush” harvesting.
VIX regime: post-FOMC, the VIX slipped below 16, but a move back toward 17–19 is anticipated into the CPI + BoE + ECB cluster (Thursday 18 Dec). That means the biotech-specific IV crush may be somewhat masked by rising index-level volatility.
Three Event-Driven Names to Watch (No View on Direction)
1) Milestone Pharmaceuticals (MIST) – Biotech / Regulatory Catalyst Completed
Status: the FDA approved CARDAMYST (etripamil nasal spray) on 13 December, as reported in GlobeNewswire. The company has confirmed the approval.
What matters now (post-approval):
- Launch dynamics: the focus shifts to the commercial rollout; early prescription data in January–February 2026 will be closely watched by the market.
- Commercial structure: MIST reported about $82.6M in cash and expects a $75M royalty milestone on approval, with a plan to build a commercial team of around 60 people.
- Pricing and reimbursement: PSVT is a niche indication (paroxysmal supraventricular tachycardia), but the company aims to expand into AFib-RVR (atrial fibrillation with rapid ventricular rate), with Phase 3 targeted for 2026. Uptake metrics will be central.
- Trading backdrop: after an approval, news-flow tends to swing around launch updates and guidance rather than binary regulatory risk.
High-level takeaway: MIST has transitioned from a “binary PDUFA” to an “execution” story; in general the focus is on commercial traction rather than on the FDA decision itself.
2) Aldeyra Therapeutics (ALDX) – Biotech / Binary Event (PDUFA 16 December)
Status: NDA for reproxalap in dry eye disease with a PDUFA target date of 16 December.
Context: Aldeyra resubmitted the NDA after two previous Complete Response Letters (CRLs) focused on efficacy questions. The third submission includes a new clinical study that met its primary endpoint (ocular discomfort reduction, P=0.002). However, the FDA has twice concluded that prior trials were not “adequate and well controlled”. That makes this third round effectively binary – approval or a third CRL.
What the market tends to watch:
- 16 December: FDA communication on approval vs. CRL; if approved, reproxalap would be positioned as an acute treatment for dry eye flares (niche but strategically interesting).
- Volatility: implied volatility is elevated into the event; historical moves in similar binaries often span the 20–50% range up or down depending on the decision.
- Downside scenario: a third CRL would likely mean a sharp drawdown; an approval often triggers a strong relief rally, after which attention shifts to commercialisation plans and funding.
High-level takeaway: ALDX is a textbook binary catalyst; any positioning around such events, in general, tends to be highly individual and risk-tolerance dependent. Here it is described purely as an example of how binary FDA setups can shape volatility, not as a view on what anyone should do.
3) Tilray Brands (TLRY) – Small Cap / Policy Catalyst (Cannabis)
Status: TLRY reacted sharply on Friday 12 December to reports about a possible easing of federal restrictions (a Trump executive order leading to rescheduling to Schedule III).
Policy-driven angles the market is following:
- Potential executive order: Trump has mentioned acting “soon in December” (for example around Monday 16 Dec), but confirmation is still uncertain. Each rumour, leak or denial has the potential to move the stock by double-digit percentages intraday.
- Banking and credit: a move to Schedule III could open the door for larger banks to service the cannabis sector, partly addressing the chronic “unbanked” problem for growers and operators.
- Longer-term narrative: if such a policy shift really materialised, investors would likely revisit assumptions around exchange listings, access to credit, and M&A potential.
- Trading backdrop: TLRY is a low-float, high-beta name; intraday volatility on policy headlines can be extreme and technical levels often take a back seat when news hits.
High-level takeaway: TLRY is essentially a policy headline vehicle; anyone approaching this type of stock generally needs to accept large gap risk. Here it is highlighted purely as an example of policy-driven volatility, not as a suggestion to take any specific position.
7) FX & Volatility
7) Macro Dynamics: EUR/USD, Rates and Implied Volatility
EUR/USD Technical Setup
EUR/USD is trading around 1.1740. The setup looks split between two broad scenarios:
Bull case: the BoE delivers a dovish cut while the ECB holds; GBP weakens versus EUR. If US CPI is also on the soft side, EUR/USD could test 1.19–1.21 in a comparatively “risk-on” environment.
Bear case: if CPI surprises to the upside and the Fed leans more hawkish again, the USD strengthens and EUR/USD could drift back toward 1.16–1.14.
Key support: 1.1612 (recent pivot), then 1.1484–1.1252 as broader floors.
Key resistance: 1.1915–1.2100 as the upper band in a bullish scenario.
Implication: EUR/USD moves drive the DXY, which in turn influences commodities, EM and the real burden of non-USD debt. For a USD-based investor, a weaker euro often supports US exporters in relative terms.
Implied Volatility and Risk Sentiment
VIX currently: around 15.77 after the Fed-driven volatility crush, below 16.
Expected move into CPI/BoE/ECB: a drift higher toward 17–19 into Thursday 18 Dec is a reasonable base case if macro surprises remain in play.
Post-decision: a classic pattern is an implied-volatility crush once the bulk of the news is out, followed by stabilisation around 16–17 into the weekend.
How Traders Often Think About This Setup (General, Not Advice)
- Short-volatility approaches (credit spreads, covered calls, outright short vega) can be challenged when implied volatility rises into macro events.
- Long-volatility structures (for example straddles and call spreads) are often used in theory to express uncertainty around the size and direction of the move.
- In biotech, the post-event IV crush is a recurring pattern, but when index-level volatility rises at the same time, the net effect on options can be more nuanced.
These are only general observations of how some market participants approach volatility, not prescriptions or suggestions.
8) Small Caps & Russell 2000
8) Sector Rotation: Russell 2000 and Small-Cap Biotech Implications
Russell 2000 Technical Setup (ATH Breakout Attempt)
The Russell 2000 is trying to break out toward new all-time highs. Based on analysis reported by OneUpTrader (11 Dec):
Key Levels
- Major resistance: 2,565 (all-time high) – a clean break above this would mark a new “price discovery” zone.
- Upper extension: 2,580–2,600 if the ATH gives way convincingly.
- First pullback support: 2,500–2,510 (recent breakout area).
- Intermediate support: 2,470 (50-day MA) – still sloping up.
- Deeper support: 2,390–2,415 (November lows, support cluster).
Momentum: RTY has rallied about 11% from the November lows (2,300–2,320), with RSI around 56 – constructive but not overbought. The trend looks bullish as long as the index holds above roughly 2,415–2,460.
Illustrative Scenario Probabilities (Next 2–3 Weeks)
- Breakout above 2,565 toward 2,600: roughly a 50% probability in this personal, non-model view – higher lows and improving momentum support this.
- Consolidation in the 2,500–2,565 band: around 35% – common behaviour near ATHs; bulls may simply need time.
- Pullback to 2,470–2,440: around 15% – more likely if global sentiment shifts sharply to risk-off after a hawkish CPI surprise.
These numbers are not a quantitative model, just a way of framing possibilities.
Implications for Small-Cap Biotech
The rotation into small caps is underpinned by several broad themes:
- Expected rate cuts: small caps are sensitive to financing costs; any perception of easier conditions in 2026 helps the Russell narrative.
- Earnings recovery: small-cap earnings are generally expected to improve in 2026 relative to mega-cap tech, where a lot of optimism may already be priced in.
- Policy tailwinds: tariffs driving reshoring, possible cannabis legalisation, and elements of deregulation can all channel flows into domestic and policy-exposed small caps.
Risk: a hawkish CPI shock on Thursday that pushes real yields higher would make a pullback in small caps more likely. The breakout is not guaranteed and can easily morph into a failed attempt if macro data disappoint.
9) Checklist
9) Practical Checklist for the Week
Pre-Week Setup (Saturday–Sunday 13–14 December)
- Post-Fed repricing: look at how markets have re-priced the 2026 cut path (median around 3.4% at end-2026, implying only a single 25 bps cut in the dots).
- Implied volatility: track VIX and IV for biotech names (MIST post-approval, ALDX pre-PDUFA, TLRY pre-policy headlines) to understand how much “event premium” is still in the options.
- Russell 2000 technicals: verify whether the 2,470–2,510 support band is still intact; in many past cases a benign CPI has allowed follow-through toward the prior ATH region.
- EUR/USD pivot: 1.1612 stands out as a key line; below that, markets tend to discuss 1.14–1.12, while a sustained hold above can keep 1.19–1.20 in play.
Day-by-Day Structure (15–19 December)
Monday 15 December:
- Open: Empire State and early Fed speakers will shape the tone for the week; weak data plus cautious but not alarmed Fed remarks often reinforce the “gradual slowdown but not recession” narrative.
Tuesday 16 December:
- Morning: Retail Sales + Flash PMIs effectively define the “growth vs. inflation” balance in the short term.
- Day: ALDX PDUFA (pre-close or early evening). Historically, binary biotech events have been catalysts for both sharp price gaps and pronounced IV moves.
- General idea (non-advisory): some traders simply monitor these binaries from the sidelines to learn about how the market prices and then re-prices them, without necessarily trading them.
Wednesday 17 December:
- Routine: oil inventories and Fed speakers; less weight than Thursday but still part of the narrative on demand and policy path.
- Observation: any hints at “forward guidance” tweaks can shift the perceived duration of the Fed’s pause.
Thursday 18 December – Key Day:
- 6:00 UK (BoE decision): a cut to 3.75% would confirm the dovish shift. Surprises (either no cut or a more dovish signal on future cuts) can affect GBP, EUR and broader risk sentiment.
- 8:00 Eurozone (ECB decision): rates expected on hold; the focus is mainly on Lagarde’s tone at 8:30 and any comments on 2026 growth.
- 13:00 US (CPI + Jobless Claims + Philly Fed):
- Headline CPI > 2.9% or core > 3.4% would likely push real yields up and pressure growth and small caps, while supporting the dollar.
- Headline < 2.7% or core < 3.1% would do the opposite, inviting talk of a “gentler” path and helping equities and high-duration assets.
Options markets often use this type of day as a focal point: implied volatility can rise into the print and compress afterwards. How to trade or not trade that, if at all, is always a personal decision; here it is mentioned purely as context.
Friday 19 December:
- Reaction to CPI: if the CPI surprise was dovish, Friday often becomes a consolidation day after a strong move. If it was hawkish, it can be a “stabilisation” attempt after an initial sell-off.
- UofM Sentiment + Home Sales: secondary inputs into risk sentiment; by this point most of the weekly tone is already set by Thursday’s data.
- Typical observation: after large moves earlier in the week, incremental risk added on Friday often has a different risk/reward profile compared to earlier entries.
Daily Monitoring (All Sessions)
- Geopolitics/Energy: headlines around Russia–Ukraine or the Middle East can still move oil and inflation expectations.
- Trump policy tape: tariff and cannabis-related announcements remain high-beta catalysts for the sectors involved.
- Fed speakers: hawkish remarks after a rally can cool sentiment; dovish nuance after a sell-off can stabilise risk.
- Options markets: watching implied volatility in small caps (ALDX, TLRY) and in Russell 2000 options can give a feel for how much hedging or de-hedging is happening in the background.
10) Final Synthesis
10) Final Synthesis: Themes & General Framework
Macro Themes
- Fed “pause” with limited dovishness: the Fed delivered a 25 bps cut, but the dots for 2026 still point to a slow, data-dependent path rather than an aggressive cutting cycle. The 18 December CPI is the key test for that balance.
- BoE–ECB divergence: a BoE cut versus an ECB hold amplifies currency-level dispersion (GBP vs. EUR) and can reinforce an EUR/USD bull case if US inflation is also benign.
- Ongoing small-cap rotation: the Russell 2000 is attempting a breakout; the story rests on easier future rates, cyclical earnings recovery and policy tailwinds such as reshoring and deregulation. The 2,565 level remains the reference point.
- Geopolitics + tariffs as tail risks: markets are not fully pricing a major event, but the tail is visible. A steep escalation in tariffs beyond 20%, for example, could re-ignite imported inflation, tighten financial conditions, and complicate the Fed’s reaction function (especially if services inflation remains sticky).
- Biotech as a volatility pocket: event-driven names can gap on FDA / company news regardless of what the index does. When macro volatility rises (CPI + central banks), biotech “IV crush” patterns can be partially offset by broader index-level repricing.
- FX as a hidden driver: moves in EUR/USD and GBP crosses can alter the tone for global risk assets and commodity-linked segments, especially if BoE surprises and the dollar re-prices on CPI.
A simple, non-advisory lens for the week
- If CPI runs hotter than expected: real yields tend to rise, the USD tends to firm, and risk appetite often shifts toward defensives and away from high-duration segments.
- If CPI comes in softer: the market often re-opens the “gentle cuts in 2026” narrative, supporting risk sentiment and helping segments that benefit from easier future financing conditions (including parts of small caps).
- If BoE/ECB messaging diverges: expect FX volatility (GBP/EUR/USD) to spill into equities via rates and cross-asset risk-parity flows.
Bottom line: this is a week where the “order of events” matters (BoE/ECB/CPI cluster). Markets can whip around on headlines, so it is often more useful to track the rates–USD–volatility chain than to focus on single equity moves in isolation.
Tools & Partners
Seeking Alpha
News and market coverage
News and market coverage
Stocktwits
Real-time trader sentiment
Real-time trader sentiment
Medved Trader
Trading platform
Trading platform
Merlintrader trading Blog
Main site
Main site
Affiliate note: some links in this section may be referral links. If you use them, it can support the site at no extra cost to you.
If you find this weekly report useful, you can support the project with a donation to help keep the site free and updated.
Disclaimer
This content is provided for informational and educational purposes only and reflects personal opinions and general market commentary. It is not investment advice, not a solicitation, and not a recommendation to buy or sell any security. Markets are risky and outcomes are uncertain. Always do your own research and consider professional advice where appropriate.
References to tickers, events, or scenarios are illustrative and may be incomplete or change without notice. Any forward-looking statements are inherently uncertain.
Legal pages:
Disclaimer |
Terms & Privacy
Biotech Catalyst Calendar
Keep an eye on upcoming FDA dates and key biotech catalysts in the calendar page:
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
